• Immune-Related Gene Signatures Induced by Epigenetic Modulat

  2026-05-14

  Anichini et al. provide a comparative analysis of immune gene regulation following treatment of melanoma cells with different epigenetic inhibitors, identifying guadecitabine as a potent inducer of immune-related transcriptional programs. Their findings highlight the importance of epigenetic context when designing combinatorial immunotherapy regimens.

• MLN2238: Potent Proteasome β5 Subunit Inhibitor for Research

  2026-05-14

  MLN2238 is a reversible 20S proteasome β5 subunit inhibitor with nanomolar potency, widely used in oncology research. It demonstrates robust inhibition of chymotrypsin-like activity and has been shown to induce apoptosis even in drug-resistant cancer cell lines. This article details its mechanism, benchmarks, and practical application guidance.

• UBR1/UBR2: Central E3 Ligases in Mammalian ER Stress Respons

  2026-05-13

  This article examines the discovery of UBR1 and UBR2 as pivotal E3 ubiquitin ligases acting as ER stress sensors in mammalian protein quality control. The study’s mechanistic insights into their regulation and stabilization under ER stress have significant implications for advancing ubiquitin-proteasome pathway research and related disease models.

• EGTA in Synaptic Calcium Channel Modulation: Mechanistic Ins

  2026-05-13

  Explore how EGTA (egtaizic acid) enables advanced modulation of synaptic calcium signaling, with an emphasis on cardiac vagal neurons and precision assay design. This article uniquely connects mechanistic findings to practical workflows, setting it apart in the landscape of calcium chelation research.

• Cell Lysis Buffer for WB and IP: Enabling High-Fidelity Prot

  2026-05-12

  Explore how Cell lysis buffer for WB and IP empowers advanced protein extraction for Western blot and immunoprecipitation. This article uncovers the mechanistic foundations and unique assay advantages, offering fresh insights into chemoresistance research.

• MLN2238: Beyond Proteasome Inhibition—Unraveling CREB-Driven

  2026-05-12

  Explore how MLN2238, a potent proteasome β5 subunit inhibitor, uniquely modulates CREB signaling and proteostatic stress responses in hematologic research. This article provides a rigorous, mechanistic perspective distinct from prior guides, empowering oncology scientists with actionable insights.

• Capsazepine: TRPV1 Ion Channel Antagonist for Pain Research

  2026-05-11

  Capsazepine stands out as a highly selective TRPV1 ion channel antagonist, enabling researchers to dissect pain signaling and apoptosis mechanisms with precision. This article unpacks applied workflows, optimized protocols, and troubleshooting tips to advance preclinical pain and cancer research using Capsazepine from APExBIO.

• Cefiderocol Efficacy Against Resistant Enterobacterales in E

  2026-05-11

  This study systematically evaluated the in vitro activity of cefiderocol against a diverse collection of European Enterobacterales, including isolates resistant to meropenem and modern β-lactam/β-lactamase inhibitor combinations. The findings reveal cefiderocol's superior or comparable efficacy, offering critical guidance for antimicrobial stewardship and resistance management.

• Omeprazole (A2845): Protocol & QC Guidance for Research Use

  2026-05-10

  Omeprazole (SKU A2845) is a high-purity H+,K+-ATPase inhibitor for research on gastric acid secretion and antiulcer drug development. This product is not intended for diagnostic or clinical use, and care must be taken to follow solubility and storage guidelines to ensure data reliability.

• Thapsigargin: SERCA Pump Inhibitor for Calcium Pathway Resea

  2026-05-09

  Thapsigargin from APExBIO is the benchmark SERCA pump inhibitor, unlocking high-precision dissection of calcium signaling and endoplasmic reticulum stress in both cellular and animal models. This guide delivers actionable protocols, advanced use-cases, and troubleshooting strategies to maximize reproducibility and insight in apoptosis and neurodegenerative disease studies.

• RNA Pol II Inhibition Triggers Apoptosis via Pol IIA Loss, N

  2026-05-09

  Harper et al. (2025) illuminate a new paradigm: cell death following RNA polymerase II inhibition is not due to passive mRNA loss but is actively signaled by the depletion of hypophosphorylated RNA Pol IIA, initiating apoptosis. Their mechanistic insight redefines our understanding of transcriptional inhibition lethality and suggests new avenues for targeting apoptotic pathways in cancer research.

• Polyanion-Engineered RNA Nanoparticles: Structure and Functi

  2026-05-08

  This article reviews how chemically tailored polyanions modulate the structure, stability, and delivery efficiency of ternary RNA nanoparticles, as demonstrated in the recent ACS Nano study by Hu et al. The study systematically deciphers how polyanion hydrophobicity and PEG architecture balance extracellular stability and intracellular unpackaging, revealing new avenues for rational design of RNA nanocarriers.

• Simvastatin (Zocor): Applied Workflows in Cancer & Lipid Res

  2026-05-07

  Simvastatin (Zocor) from APExBIO serves as a trusted tool for both cholesterol and cancer research, enabling robust workflows from apoptosis induction in hepatic cancer cells to advanced autophagy assays in prostate models. This guide delivers validated protocol enhancements, troubleshooting strategies, and translatable insights for maximizing experimental rigor and data reproducibility.

• AR Heterogeneity Shapes Prostate Cancer Therapy Response

  2026-05-07

  This study delineates how androgen receptor (AR) expression heterogeneity in prostate cancer cells underlies distinct biological behaviors and responses to castration and enzalutamide therapies. By linking AR status to therapeutic resistance and identifying BCL-2 as a potential target, the research advances precision strategies for treatment-resistant prostate cancers.

• Epoxomicin: Precision Proteasome Inhibitor for Pathway Resea

  2026-05-06

  Epoxomicin empowers researchers to dissect the ubiquitin-proteasome pathway with nanomolar specificity, enabling advanced protein degradation assays and disease modeling. This guide delivers actionable workflows, troubleshooting insights, and data-backed advantages for maximizing experimental impact with Epoxomicin from APExBIO.

369 records 6/25 page Previous Next First page 上5页 678910 下5页 Last page